Murine double minute 2 as a therapeutic target for radiation sensitization of lung cancer

Molecular Cancer Therapeutics

Volumn 4, Issue 8, 2005, Pages 1137-1145

  Cao, Carolyn ^a   Shinohara, Eric T ^a   Niermann, Kenneth J ^a   Donnelly, Edwin F ^a   Chen, Xinping ^a   Hallahan, Dennis E ^a   Lu, Bo ^a,b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 AMINODACTINOMYCIN; ANTISENSE OLIGONUCLEOTIDE; PROTEIN MDM2; PROTEIN P21; PROTEIN P53;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER MODEL; CANCER RADIOTHERAPY; CELL AGING; CELL MIGRATION; CELL SURVIVAL; CELL VIABILITY; CLONOGENIC ASSAY; CONTROLLED STUDY; DNA DAMAGE; DOPPLER ECHOGRAPHY; FEMALE; GENETIC TRANSFECTION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IRRADIATION; LUNG CANCER; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; RADIOSENSITIVITY; RADIOSENSITIZATION; STAINING; STATISTICAL ANALYSIS; TUMOR BLOOD FLOW; TUMOR VASCULARIZATION; UMBILICUS; VASCULAR ENDOTHELIUM; XENOGRAFT;

ANIMALS; APOPTOSIS; CELL AGING; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; ENDOTHELIUM, VASCULAR; HUMANS; LUNG NEOPLASMS; MICE; NUCLEAR PROTEINS; OLIGONUCLEOTIDES, ANTISENSE; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-MDM2; RADIATION-SENSITIZING AGENTS; TRANSFECTION; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UMBILICAL CORD; UP-REGULATION;

EID: 23844464792     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-04-0327     Document Type: Article

References (42)

1. Wang H, Nan L, Yu D, Agrawal S, Zhang R. Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. Clin Cancer Res 2001;11:3613-24.
2. Freedman DA, Levine AJ. Regulation of the p53 protein by the MDM2 oncoprotein - thirty-eighth G.H.A. Clowes Memorial Award lecture. Cancer Res 1999;1:1-7.
3. Woods DB, Vousden KH. Regulation of p53 function. Exp Cell Res 2001;1:56-66.
4. Wang H, Oliver P, Zhang Z, Agrawal S, Zhang R. Chemosensitization and radiosensitization of human cancer by antisense anti-MDM2 oligonucleotides: in vitro and in vivo activities and mechanisms. Ann N Y Acad Sci 2003;1002:217-35.
5. Zhang Z, Wang H, Li M, Agrawal S, Chen X, Zhang R. MDM2 is a negative regulator of p21WAF1/CIP1, independent of p53. J Biol Chem 2004;16:16000-6.
6. Chen J, Wu X, Lin J, Levine AJ. mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 1996;5:2445-52.
7. Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53. Nature 1997;6630:296-9.
8. Mu Z, Hachem P, Agrawal S, Pollack A. Antisense MDM2 sensitizes prostate cancer cells to androgen deprivation, radiation, and the combination. Int J Radiat Oncol Biol Phys 2004;2:336-43.
9. Dilla T, Romero J, Sanstisteban P, Velasco JA. The mdm2 proto-oncogene sensitizes human medullary thyroid carcinoma cells to ionizing radiation. Oncogene 2002;15:2376-86.
10. Zhang Z, Li M, Wang H, Agrawal S, Zhang R. Antisense therapy targeting MDM2 oncogene in prostate cancer: Effects on proliferation, apoptosis, multiple gene expression, and chemotherapy. Proc Natl Acad Sci U S A 2003;20:11636-41.
11. Dotto GP. p21(WAF1/Cip1): more than a break to the cell cycle? Biochim Biophys Acta 2000;1:M43-56.
12. Helene C, Toulme JJ. Specific regulation of gene expression by antisense, sense and antigene nucleic acids. Biochim Biophys Acta 1990; 2:99-125.
13. Peyman A, Helsberg M, Kretzschmar G, Mag M, Grabley S, Uhlmann E. Inhibition of viral growth by antisense oligonucleotides directed against the IE110 and the UL30 mRNA of herpes simplex virus type-1. Biol Chem Hoppe Seyler 1995;3:195-8.
14. Smith L, Andersen KB, Hovgaard L, Jaroszewski JW. Rational selection of antisense oligonucleotide sequences. Eur J Pharm Sci 2000;3:191-8.
15. Crooke ST. Progress in antisense therapeutics. Hematol Pathol 1995;2:59-72.
16. Chen L, Agrawal S, Zhou W, Zhang R, Chen J. Synergistic activation of p53 by inhibition of MDM2 expression and DNA damage. Proc Natl Acad Sci U S A 1998;1:195-200.
17. Edwards E, Geng L, Tan J, Onishko H, Donnelly E, Hallahan DE. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res 2002;16:4671-7.
18. Geng L, Donnelly E, McMahon G, et al. Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 2001;6:2413-9.
19. Bao R, Connolly DC, Murphy M, et al. Activation of cancer-specific gene expression by the survivin promoter. J Natl Cancer Inst 2002;7: 522-8.
20. Rodel C, Haas J, Groth A, Grabenbauer GG, Sauer R, Rodel F. Spontaneous and radiation-induced apoptosis in colorectal carcinoma cells with different intrinsic radiosensitivities: survivin as a radioresistance factor. Int J Radiat Oncol Biol Phys 2003;5:1341-7.
21. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53 dependent and independent pathways. Nature 1993; 6423:849-52.
22. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res 1991;23 Pt 1:6304-11.
23. Zhang Z, Wang H, Prasad G, et al. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clin Cancer Res 2004;4:1263-73.
24. Vogelstein B, Kinzler KW. p53 function and dysfunction. Cell 1992; 4:523-6.
25. Livingstone LR, White A, Sprouse J, Livanos E, Jacks T, Tlsty TD. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992;6:923-35.
26. Kastan MB, Zhan Q, el-Deiry WS, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 1992;4:587-97.
27. Zakut-Houri R, Bienz-Tadmor B, Givol D, Oren M. Human p53 cellular tumor antigen: cDNA sequence and expression in COS cells. EMBO J 1985;5:1251-5.
28. Perry ME, Piette J, Zawadzki JA, Harvey D, Levine AJ. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. Proc Natl Acad Sci U S A 1993;24:11623-7.
29. Chen CY, Oliner JD, Zhan Q, Fornace AJ Jr, Vogelstein B, Kastan MB. Interactions between p53 and MDM2 in a mammalian cell cycle checkpoint pathway. Proc Natl Acad Sci U S A 1994;7:2684-8.
30. Perry ME. Mdm2 in the response to radiation. Mol Cancer Res 2004; 1:9-19.
31. Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature 1997;6630:299-303.
32. Freedman DA, Levine AJ. Nuclear export is required for degradation of endogenous p53 by MDM2 and human papillomavirus E6. Mol Cell Biol 1998;12:7288-93.
33. Grunbaum U, Meye A, Bache M, et al. Transfection with mdm2-antisense or wtp53 results in radiosensitization and an increased apoptosis of a soft tissue sarcoma cell line. Anticancer Res 2001;3B: 2065-71.
34. Maier B, Gluba W, Bernier B, et al. Modulation of mammalian life span by the short isoform of p53. Genes Dev 2004;3:306-19.
35. Ghosh A, Stewart D, Matlashewski G. Regulation of human p53 activity and cell localization by alternative splicing. Mol Cell Biol 2004;18:7987-97.
36. Brown JP, Wei W, Sedivy JM. Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 1997;5327:831-4.
37. Gire V, Wynford-Thomas D. Reinitiation of DNA synthesis and cell division in senescent human fibroblasts by microinjection of anti-p53 antibodies. Mol Cell Biol 1998;3:1611-21.
38. Dameron KM, Volpert OV, Tainsky MA, Bouck N. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 1994;5178:1582-4.
39. Van Meir EG, Polverini PJ, Chazin VR, Su Huang HJ, de Tribolet N, Cavenee WK. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet 1994;2:171-6.
40. Mukhopadhyay D, Tsiokas L, Sukhatme VP. Wild-type p53 and v-Src exert opposing influences on human vascular endothelial growth factor gene expression. Cancer Res 1995;24:6161-5.
41. Bouvet M, Ellis LM, Nishizaki M, et al. Adenovirus-mediated wild-type p53 gene transfer down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in human colon cancer. Cancer Res 1998;11:2288-92.
42. Fontanini G, Boldrini L, Vignati S, et al. Bcl2 and p53 regulate vascular endothelial growth factor (VEGF)-mediated angiogenesis in non-small cell lung carcinoma. Eur J Cancer 1998;5:718-23.